Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                MCM Issues

MCM Issues

                        Advanced Manufacturing
          Antimicrobial Resistance Information from FDA
          Ebola Preparedness and Response Updates from FDA
          FDA/DoD Collaborations
          FDA Mpox Response
          Medical Countermeasure Monitoring and Assessment
          Pediatric Medical Countermeasures
          Preparedness Information for Consumers
          Radiological and Nuclear Emergency Preparedness Information from FDA
          Smallpox Preparedness and Response Updates from FDA
          Zika Virus Response Updates from FDA Home
          Emergency Preparedness and Response
          Counterterrorism and Emerging Threats
          Medical Countermeasures Initiative (MCMi)
          MCM Issues
          Medical Countermeasure Monitoring and AssessmentMCM Issues Medical Countermeasure Monitoring and Assessment
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintImage
              Electronic health records are an important part of post-dispensing medical countermeasure monitoring and assessment


  Caption
        
      Electronic health records are an important part of post-dispensing medical countermeasure monitoring and assessmentBackground | FDA Guidance & Regulatory Information | Contact | FDA MCM Monitoring & Assessment Projects| Medical Product Assessment in General | Additional Resources

Background

There is a critical need for the U.S. Government (USG) to build and maintain a national capability to monitor and assess medical countermeasures (MCMs) after they are dispensed or administered in response to a chemical, biological, radiological, or nuclear threat or an emerging infectious disease.  In collaboration with the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), FDA has been a key partner in developing such a capability.

Historically, research as part of a public health emergency response has been limited. However, that is changing. Experiences responding to public health emergencies highlight the need for a coordinated plan to leverage every opportunity to learn more about an MCM’s performance.  This information is vital to protecting public health, particularly in the case of MCMs that may have limited human efficacy data prior to their use.  The emergency may present the only opportunity for clinical assessment.

The resources below highlight relevant FDA guidance and regulatory information, specific FDA projects related to monitoring and assessment of MCMs, some of the ongoing FDA work related to medical product assessment in general, and key efforts relevant to MCMs that are ongoing outside of FDA.

FDA Guidance & Regulatory Information

FDA guidance and general FDA regulatory information to provide important context on the need for MCM monitoring and assessment:

Guidances and other information of special interest to MCM stakeholders (including the January 2017 guidance on Emergency Use Authorization of Medical Products and Related Authorities; October 2015 guidance on Product Development Under the Animal Rule (PDF, 574 KB); and the June 2016 guidance on Expanded Access to Investigational Drugs for Treatment Use (PDF, 180 KB))
	Animal Rule Information - In developing MCMs for potential bioterror threats, human challenge studies (exposing people to the threat agent) are often not ethical or feasible. In these cases, FDA may grant approval based on well-controlled animal studies, when the results of those studies establish that the drug or biologic product is reasonably likely to produce clinical benefit in humans. The product sponsor must still demonstrate the product’s safety in humans.
	FDA Postmarketing Requirements and Commitments - Postmarketing requirements and commitments refer to studies and clinical trials that sponsors conduct after approval to gather additional information about a product's safety, efficacy, or optimal use.FDA Contact

FDA Medical Countermeasures Initiative (MCMi)AskMCMi@fda.hhs.gov

*NOTE: Non-FDA links below are included for reference, and do not necessarily reflect FDA's positions or opinions. Consistent with FDA website policies and disclaimer, reference in any referred (linked) website to commercial products, services, manufacturers, or companies does not constitute an endorsement by the U.S. government, the Department of Health and Human Services, or FDA.*

FDA Information about Past and Current MCM Monitoring and Assessment Projects

FDA Sentinel System’s Coronavirus (COVID-19) Activities
	FDA’s Sentinel System is engaged in numerous activities to protect and promote public health during the COVID-19 pandemic, including an ongoing project led by the FDA Office of Counterterrorism and Emerging Threats (OCET) to examine outcomes among hospitalized patients with influenza-like illness and acute respiratory disease that is being expanded to also capture data on hospitalized patients diagnosed with COVID-19.
	Using a Handheld Device for Patient Data Collection: A Pilot for Medical Countermeasures Surveillance
	This project demonstrated the feasibility of using a handheld device to collect patient information and accurately link individuals to their health record.
	Adverse Events Monitoring and Analysis Pilot Program (completed MCMi Regulatory Science project)
	This project assessed the feasibility of rapidly detecting, verifying, and assessing adverse events to conduct risk-benefit analyses during emergency situations and communicate related risk.
	Influenza antiviral drug use 2010-2015
	This study involved a modular program-based, one-time assessment of incident use of two influenza antiviral drugs (Oseltamivir and Zanamivir) during the five previous influenza seasons (2010-2015).
	Streamlining Countermeasure Data Collection During Public Health Emergencies
	In collaboration with the Biomedical Advanced Research and Development Authority, FDA awarded Discovery, the Critical Care Research Network, a contract to help speed access to and evaluation of MCMs during public health emergencies.
	FDA Real Time Application for Portable Interactive Devices (RAPID)
	FDA’s Real-Time Application for Portable Interactive Devices (RAPID) is a real-time bidirectional communication and analytic system that is customizable to respond to emergency and general FDA requirements for safety and patient outcome surveillance.
	Use of an FDA Real-time Mobile Communication Platform System during Medical Countermeasure Events: RAPID
	May 31, 2017 presentation at the 2017 FDA Science Forum by Henry "Skip" Francis, MD, Director for Data Mining and Informatics Evaluation and Research, CDER (recording at 53:20 – 1:11:00)
	Building a National Capability to Monitor and Assess MCM Use in Response to Public Health Emergencies
	June 6, 2017: Presentation by FDA's RADM Carmen T. Maher on medical countermeasure monitoring and assessment (slides from keynote at the NAS workshop listed immediately above).
	Building a National Capability to Monitor and Assess Medical Countermeasure Use During a Public Health Emergency: Going Beyond the Last Mile: Proceedings of a Workshop
	October 31, 2017: Proceedings of the June 2017 NASEM workshop to further discussion on the need for a more robust national capability for monitoring and assessing MCMs during public health emergencies.
	Descriptive Analyses in the Sentinel System for the FDA Office of Counterterrorism and Emerging Threats (OCET)
	July 18, 2018 (posted): OCET-sponsored project to explore how the Sentinel System may inform study protocols for MCM safety and effectiveness, and to provide a baseline for comparison during a public health emergency.
	Public Health Emergencies: Unpacking Medical Countermeasures Management for Preparedness and Response
	September 7, 2018: Article in the *American Journal of Public Health*.
	Examining the Ability to Conduct Influenza Antiviral Effectiveness Studies in Sentinel by Improving Confounding Control
	March 21, 2019 (posted): OCS/OCET-sponsored project to explore how the Sentinel System may inform study protocols for medical countermeasure safety and effectiveness and to provide a valuable baseline for comparison during a public health emergency.FDA Information regarding Medical Product Assessment in General

Public information from FDA about monitoring and assessment of medical products for safety and effectiveness

FDA Sentinel Initiative
	FDA’s Sentinel System is an active surveillance system that uses routine querying tools and pre-existing electronic healthcare data from multiple sources to monitor the use and safety of regulated medical products.
	CBER Biologics Effectiveness and Safety (BEST) System
	Launched in October 2017 to expand and enhance CBER access to new and better data sources, methods, tools, expertise and infrastructure to conduct surveillance and epidemiologic studies. BEST is part of the Sentinel initiative and it promotes CBER's Office of Biostatistics and Epidemiology's (OBE) mission to assure the safety and effectiveness of biologic products including vaccines, blood and blood products, tissues and advanced therapeutics.
	CDER Conversation: The FDA's Sentinel Initiative (November 2017)
	Robert Ball, MD, MPH, deputy director of CDER’s Office of Surveillance and Epidemiology, discusses Sentinel’s progress and future.
	Sentinel Post-licensure Rapid Immunization Safety Monitoring (PRISM) Program (archived FDA Voice blog post)
	PRISM, a component of FDA’s Sentinel initiative, is an active national vaccine safety surveillance system used to evaluate for vaccine-adverse events.
	National Evaluation System for health Technology (NEST)
	FDA is building the foundation for a National Evaluation System for health Technology (NEST) to more efficiently generate better evidence for medical device evaluation and regulatory decision-making.
	Medical Device Epidemiology Network Initiative (MDEpiNet)
	The MDEpiNet initiative is a collaborative program through which FDA’s Center for Devices and Radiological Health and external partners share information and resources to enhance our understanding of the safety and effectiveness of medical devices.
	FDA Adverse Event Reporting System (FAERS)
	FAERS is a database designed to support the FDA's post-marketing safety surveillance program for drug and therapeutic biologic products that contains information on adverse event and medication error reports submitted to FDA.
	Vaccine Adverse Event Reporting System (VAERS)
	VAERS is a national vaccine safety surveillance program co-sponsored by FDA and CDC to detect possible signals of adverse events associated with vaccines.
	Innovation in Medical Evidence Development and Surveillance (IMEDS) Program
	The IMEDS program, offered by the Reagan-Udall Foundation for the FDA, serves to advance the science and tools necessary to support post-market evidence generation on regulated products.
	Health Informatics at FDA
	Health informatics initiatives at FDA combine the disciplines of information science, computer science, medicine, data science, and management science to evaluate and enable access to life-sustaining and life-saving products.
	Leveraging Real-World Data and Shared Clinical Trial Data to Inform Regulatory Decision-Making (Yale University-Mayo Clinic)
	FDA has awarded Yale and Mayo Clinic a grant to establish a Center of Excellence in Regulatory Science and Innovation related to leveraging real-world data and shared clinical trial data to inform regulatory decision-making.
	Use of Electronic Health Record Data in Clinical Investigations - Guidance for Industry (PDF, 327 KB)
	July 2018 - to assist sponsors, clinical investigators, contract research organizations, institutional review boards, and others on the use of electronic health record data in FDA- regulated clinical investigations.Additional Resources

Resources from other sources, including other government agencies, relevant to monitoring and assessment of MCMs

PHEMCE Strategy and Implementation Plan
	The PHEMCE annually assesses and updates a PHEMCE Strategy and Implementation Plan to ensure that PHEMCE priorities reflect current scientific progress and fiscal capabilities and to ensure optimal allocation of resources to address high-priority threats.
	BARDA core services, including CSN
	The BARDA Clinical Studies Network (CSN) is a network of clinical research organizations established to design and conduct clinical studies needed to develop MCMs.
	NIH Health Care Systems Research Collaboratory
	The NIH Collaboratory aims to strengthen the national capacity to implement cost-effective large-scale research studies that engage healthcare delivery organizations as research partners.
	NIH Disaster Research Response Program (DR2)
	The NIH Disaster Research Response Program (DR2) is the national framework for research on the medical and public health aspects of disasters and public health emergencies.
	HHS ASPR Technical Resources, Assistance Center, and Information Exchange (TRACIE)
	ASPR TRACIE was created to meet the information and technical assistance needs of regional ASPR staff, healthcare coalitions, healthcare entities, healthcare providers, emergency managers, public health practitioners, and other relevant stakeholders.
	CDC Vaccine Safety Datalink (VSD)
	The VSD is a collaborative project between CDC's Immunization Safety Office and nine health care organizations to monitor safety of vaccines and conduct studies about rare and serious adverse events following immunization.
	CDC Division of Health Informatics and Surveillance (DHIS)
	CDC's DHIS manages two public health surveillance programs that have cross-cutting utility for multiple CDC programs and public health jurisdictions.
	NAS Real-World Evidence Generation and Evaluation of Therapeutics A Workshop
	October 2016 public workshop hosted by NAS that examined opportunities and challenges for incorporating real-world evidence into evaluation of medical products.
	NAS Standing Committee on Medical and Public Health Research During Large-Scale Emergency Events
	Standing committee hosted by NAS that provides a venue for discussion of issues related to short- and long-term strategic planning
	Discovery, the Critical Care Research Network, University of Southern California
	Fosters collaborative research to promote the advancement of science in the field to improve outcomes for critically ill and injured patients.
	PCORnet, the National Patient-Centered Clinical Research Network
	PCORnet is designed to make it faster, easier, and less costly to conduct clinical research than is now possible by harnessing the power of large amounts of health data and patient partnerships.
	Observational Health Data Sciences and Informatics (OHDSI)
	The OHDSI program is a multi-stakeholder, interdisciplinary collaborative to bring out the value of health data through large-scale analytics.

                                                                                  Content current as of:
      12/16/2022
              
              
Regulated Product(s)
		 Biologics
			  			     			  			     Drugs
			     			  			     Medical DevicesTopic(s)
			  Emergency Response
				    				       				    				       Terrorism
				       				    				       Radiological
				       				    				       Outbreak
				       				    				       Chemical
				       				    				       Biological
				       				    				       Postmarket
				       				    					
				  
				    
				  Animal Rule
				  				     				  				  
				  
				  
				   
				  
				  				  SurveillanceMCM Issues

          
                        Advanced Manufacturing
          Antimicrobial Resistance Information from FDA
          Ebola Preparedness and Response Updates from FDA
          FDA/DoD Collaborations
          FDA Mpox Response
          Medical Countermeasure Monitoring and Assessment
          Pediatric Medical Countermeasures
          Preparedness Information for Consumers
          Radiological and Nuclear Emergency Preparedness Information from FDA
          Smallpox Preparedness and Response Updates from FDA
          Zika Virus Response Updates from FDA
 Subscribe
                        Sign up to receive email alerts on emergency preparedness and response topics from FDA, including medical countermeasures and emerging infectious diseases.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop